“SAN FRANCISCO, CA — October 11, 2005 — Methicillin-resistance occurred in almost half of all patients with Staphylococcus aureus who were treated for skin and skin structure infections in Phase 3 studies of a new antibiotic aimed at controlling resistant bacteria.”
High Rate of Methicillin-resistant Staphylococcus Infection Seen in Dalbavancin Phase 3 Trials: Presented at IDSA
October 12th, 2005 · No Comments
Tags: MRSA Drugs
.gif)
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
Leave a Comment